File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases

TitleViral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases
Authors
KeywordsEpstein-Barr virus
lymphoproliferative diseases
viral-targeted strategies
EBV latency
lytic cycle reactivation
Issue Date2019
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology
Citation
Frontiers in Oncology, 2019, v. 9, p. article no. 81 How to Cite?
AbstractEpstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferative diseases (EBV-LPDs) ranging from post-transplant lymphoproliferative disorder, B cell lymphomas (e.g., endemic Burkitt lymphoma, Hodgkin lymphoma, and diffuse large B cell lymphoma) to NK or T cell lymphoma (e.g., nasal NK/T-cell lymphoma). The virus expresses a number of latent viral proteins which are able to manipulate cell cycle and cell death processes to promote survival of the tumor cells. Several FDA-approved drugs or novel compounds have been shown to induce killing of some of the EBV-LPDs by inhibiting the function of latent viral proteins or activating the viral lytic cycle from latency. Here, we aim to provide an overview on the mechanisms by which EBV employs to drive the pathogenesis of various EBV-LPDs and to maintain the survival of the tumor cells followed by a discussion on the development of viral-targeted strategies based on the understanding of the patho-mechanisms.
Persistent Identifierhttp://hdl.handle.net/10722/290630
ISSN
2020 Impact Factor: 6.244
2020 SCImago Journal Rankings: 1.834
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHui, KF-
dc.contributor.authorYIU, SPT-
dc.contributor.authorTAM, KP-
dc.contributor.authorChiang, AKS-
dc.date.accessioned2020-11-02T05:44:55Z-
dc.date.available2020-11-02T05:44:55Z-
dc.date.issued2019-
dc.identifier.citationFrontiers in Oncology, 2019, v. 9, p. article no. 81-
dc.identifier.issn2234-943X-
dc.identifier.urihttp://hdl.handle.net/10722/290630-
dc.description.abstractEpstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferative diseases (EBV-LPDs) ranging from post-transplant lymphoproliferative disorder, B cell lymphomas (e.g., endemic Burkitt lymphoma, Hodgkin lymphoma, and diffuse large B cell lymphoma) to NK or T cell lymphoma (e.g., nasal NK/T-cell lymphoma). The virus expresses a number of latent viral proteins which are able to manipulate cell cycle and cell death processes to promote survival of the tumor cells. Several FDA-approved drugs or novel compounds have been shown to induce killing of some of the EBV-LPDs by inhibiting the function of latent viral proteins or activating the viral lytic cycle from latency. Here, we aim to provide an overview on the mechanisms by which EBV employs to drive the pathogenesis of various EBV-LPDs and to maintain the survival of the tumor cells followed by a discussion on the development of viral-targeted strategies based on the understanding of the patho-mechanisms.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology-
dc.relation.ispartofFrontiers in Oncology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectEpstein-Barr virus-
dc.subjectlymphoproliferative diseases-
dc.subjectviral-targeted strategies-
dc.subjectEBV latency-
dc.subjectlytic cycle reactivation-
dc.titleViral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases-
dc.typeArticle-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fonc.2019.00081-
dc.identifier.pmid30873380-
dc.identifier.pmcidPMC6400835-
dc.identifier.scopuseid_2-s2.0-85063263950-
dc.identifier.hkuros317765-
dc.identifier.volume9-
dc.identifier.spagearticle no. 81-
dc.identifier.epagearticle no. 81-
dc.identifier.isiWOS:000459690900001-
dc.publisher.placeSwitzerland-
dc.identifier.issnl2234-943X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats